Recurrent PRDM10 Fusions in Superficial CD34-Positive Fibroblastic Tumors : A Clinicopathologic and Molecular Study of 10 Additional Cases of an Emerging Novel Entity
American Journal of Clinical Pathology · 2023
DOI: 10.1093/ajcp/aqac171 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Clinical Pathology, 2023. Verfasst von Ming Zhao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Cancer Center, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, China. Hauptthemen laut MEDLINE: Soft Tissue Neoplasms, Neoplasms, Connective and Soft Tissue. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Zhejiang Provincial Natural Science Foundation, Zhejiang Provincial Medicine and Health Research Foundation, Natural Science Foundation of Zhejiang Province.
Abstract (Originalsprache)
Objectives
Superficial CD34-positive fibroblastic tumor (SCD34FT) is a rare mesenchymal neoplasm. The genetic alterations of SCD34FT have yet to be determined. Recent studies suggest it overlaps with PRDM10-rearranged soft tissue tumor (PRDM10-STT).
Methods
This study aimed to characterize a series of 10 cases of SCD34FT using fluorescence in situ hybridization (FISH) and targeted next-generation sequencing (NGS).
Results
The study recruited 7 men and 3 women aged between 26 and 64 years. The tumors were located in the superficial soft tissues of the thigh (8 cases), foot, and back (1 case each), ranging in size from 1.5 to 7 cm. The tumors were composed of sheets and fascicles of plump spindled to polygonal cells, with glassy cytoplasm and pleomorphic nuclei. Mitotic activity was absent or low. Common and uncommon stromal findings included foamy histiocytic infiltrates, myxoid changes, peripheral lymphoid aggregates, large ectatic vessels, arborizing capillary vasculature, and hemosiderin deposition. All tumors expressed CD34, and 4 demonstrated focal cytokeratin immunoexpression. In 7 of 9 (77.8%) cases analyzed, FISH identified PRDM10 rearrangement. Targeted NGS revealed a MED12::PRDM10 fusion in 4 of 7 cases tested. Follow-up showed no recurrence or metastasis.
Conclusions
We demonstrate recurrent PRDM10 rearrangements in SCD34FT and provide additional evidence of a close relationship to PRDM10-STT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Cancer Center, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, China.
- Department of Pathology, Hangzhou Women's Hospital, Hangzhou, China.
- Department of Pathology, School of Basic Medical Sciences, Third Hospital, Peking University Health Science Center, Beijing, China.
- Department of Breast Surgery, Cancer Center, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, China.
ORCID-Profile: Ming Zhao
Förderung
- Zhejiang Provincial Natural Science Foundation
- Zhejiang Provincial Medicine and Health Research Foundation
- Natural Science Foundation of Zhejiang Province
Zitieren
APA
Zhao, M., Yin, X., He, H., Fan, Y., Ru, G., & Meng, X. (2023). Recurrent PRDM10 Fusions in Superficial CD34-Positive Fibroblastic Tumors : A Clinicopathologic and Molecular Study of 10 Additional Cases of an Emerging Novel Entity. American Journal of Clinical Pathology. https://doi.org/10.1093/ajcp/aqac171
Vancouver
Zhao M, Yin X, He H, Fan Y, Ru G, Meng X. Recurrent PRDM10 Fusions in Superficial CD34-Positive Fibroblastic Tumors : A Clinicopathologic and Molecular Study of 10 Additional Cases of an Emerging Novel Entity. American Journal of Clinical Pathology. 2023. doi:10.1093/ajcp/aqac171
BibTeX
@article{Zhao2023,
author = {Zhao, Ming and Yin, Xiaona and He, Huiying and Fan, Yuqian and Ru, Guoqing and Meng, Xuli},
title = {Recurrent PRDM10 Fusions in Superficial CD34-Positive Fibroblastic Tumors : A Clinicopathologic and Molecular Study of 10 Additional Cases of an Emerging Novel Entity},
journal = {American Journal of Clinical Pathology},
year = {2023},
doi = {10.1093/ajcp/aqac171}
}
EUVIMED